Volume 19 Issue 11
Nov.  2021
Turn off MathJax
Article Contents
Article Navigation >  Chinese Journal of General Practice  > 2021  >  19(11): 1861-1863,1950
MAO Huan-hao, YE Jian-fei, ZHENG Wei-feng, YANG Ying. Effect of levosimendan combined with lyophilised recombinant human brain natriuretic peptide on ventricular remodelling in patients with ischemic cardiomyopathy[J]. Chinese Journal of General Practice, 2021, 19(11): 1861-1863,1950. doi: 10.16766/j.cnki.issn.1674-4152.002186
Citation: MAO Huan-hao, YE Jian-fei, ZHENG Wei-feng, YANG Ying. Effect of levosimendan combined with lyophilised recombinant human brain natriuretic peptide on ventricular remodelling in patients with ischemic cardiomyopathy[J]. Chinese Journal of General Practice, 2021, 19(11): 1861-1863,1950. doi: 10.16766/j.cnki.issn.1674-4152.002186
shu

Effect of levosimendan combined with lyophilised recombinant human brain natriuretic peptide on ventricular remodelling in patients with ischemic cardiomyopathy

doi: 10.16766/j.cnki.issn.1674-4152.002186
  • 1.

    Department of Cardiology, the Fourth Hospital of Ningbo City, Ningbo, Zhejiang 315700, China

Funds:

 2018KY492

  • Received Date: 2021-04-19
    Abstract
  •   Objective  To observe the clinical efficacy of levosimendan combined with lyophilised recombinant human brain natriuretic peptide (neoactivin) in the treatment of ischemic cardiomyopathy and the improvement of cardiac function damage and ventricular remodelling.  Methods  A total of 240 patients with ischemic cardiomyopathy heart failure admitted to the Department of Cardiology in Ningbo Fourth Hospital from June 2018 to February 2021 were selected as the research objects. The patients were randomly divided into the control group (120 cases) and study group (120 cases) according to the random number table method. The patients in the control group were given conventional treatment, whilst those in the study group were treated with levosimendan combined with neoactivin. The serum levels of TGF-β1, NF-κB, FGF23, CysC, CK-MB, NT-proBNP and hs-CRP in both groups before and after treatment were detected. The changes in LVEDD, LVESD, LVEDV, LVESV and LVEF were statistically analysed. The clinical efficacy of heart failure after treatment was evaluated. The 6-min walk test was conducted. The incidence of adverse drug reactions during treatment was observed.  Results  After treatment, serum levels of NF-κB, CysC, CK-MB, NT-proBNP and hs-CRP in the study group were significantly lower than those in the control group (all P < 0.05). The detection values of LVEDV and LVESV in the study group were significantly lower than those in the control group, whilst LVEF (54.18±4.94) % was significantly higher than that in the control group (49.62±4.61) % (all P < 0.05). The total effective rate of the study group (90.83%) was significantly higher than that of the control group (76.67%, P < 0.05). The results of the 6-min walk test in the study group [(436.51±33.82) m] was significantly better than that in the control group [(392.74±28.61) m, P < 0.05]. No adverse drug reactions were observed in both groups during treatment.  Conclusion  Levosimendan combined with neoactivin can effectively alleviate ventricular remodelling, inhibit myocardial injury, improve myocardial function, improve the level of curative effect and has high safety.

     

    • FullText(HTML)
  • loading
    • References(17)
  • [1]
    姜丹.心肌梗死后缺血性心肌病的相关危险因素分析[J].中西医结合心血管病电子杂志,2018,6(5):100,102. https://www.cnki.com.cn/Article/CJFDTOTAL-ZXJH201805068.htm
    [2]
    薛彦博,郑小璞.缺血性心肌病的诊断与治疗现状:局限与展望[J].中华临床医师杂志(电子版),2016,10(6):763-765. doi: 10.3877/cma.j.issn.1674-0785.2016.06.002
    [3]
    张莉,郑颜磊,程飞.细胞凋亡在缺血性心肌病中作用的研究进展[J].中国中西医结合急救杂志,2018,25(5):558-560. doi: 10.3969/j.issn.1008-9691.2018.05.029
    [4]
    安雅芳,马娜.缺血性心肌病的临床研究进展[J].中国处方药,2017,15(10):16-17. doi: 10.3969/j.issn.1671-945X.2017.10.012
    [5]
    李静.冠状动脉硬化性缺血性心肌病的临床特点[J].中西医结合心血管病电子杂志,2020,8(9):71,90. https://www.cnki.com.cn/Article/CJFDTOTAL-ZXJH202009054.htm
    [6]
    龙竞伟,李平.曲美他嗪联合比索洛尔对缺血性心肌病患者NT-proBNP水平及心功能的影响[J].中华全科医学,2020,18(5):766-768. https://www.cnki.com.cn/Article/CJFDTOTAL-SYQY202005018.htm
    [7]
    潘春奇,菅颖,倪斌,等.沙库巴曲缬沙坦对射血分数降低的缺血性心肌病患者心肌损伤和炎症因子的影响[J].中华全科医学,2020,18(11):1848-1850,1945. https://www.cnki.com.cn/Article/CJFDTOTAL-SYQY202011016.htm
    [8]
    李玮,穆少丽.冻干重组人脑利钠肽对缺血性心肌病合并心力衰竭患者神经内分泌激素及心室重构的影响[J].广西医科大学学报,2018,35(7):947-951. https://www.cnki.com.cn/Article/CJFDTOTAL-GXYD201807014.htm
    [9]
    陈如杰,郭献阳,程碧环,等.左西孟旦对应激性心肌病患者的心脏保护作用[J].中华危重症医学杂志(电子版),2017,10(6):381-385. doi: 10.3877/cma.j.issn.1674-6880.2017.06.004
    [10]
    顾方方,程震锋.左西孟旦联合中药治疗扩张型心肌病伴心力衰竭临床研究[J].中华中医药学刊,2017,35(10):2634-2637. https://www.cnki.com.cn/Article/CJFDTOTAL-ZYHS201710042.htm
    [11]
    王江友,鄢华.左西孟旦在心血管疾病中的多效性研究进展[J].中华老年心脑血管病杂志,2018,20(3):312-313. doi: 10.3969/j.issn.1009-0126.2018.03.025
    [12]
    吴刚,周宇.左西孟旦对老年慢性心力衰竭心室重构及相关指标的影响[J].中华老年心脑血管病杂志,2020,22(4):393-396. doi: 10.3969/j.issn.1009-0126.2020.04.015
    [13]
    颜成敏,葛赟,周瑜,等.重组人脑利钠肽对急性失代偿性心功能衰竭合并急性肾功能损伤的临床疗效观察[J].中华急诊医学杂志,2018,27(9):1041-1043. doi: 10.3760/cma.j.issn.1671-0282.2018.09.018
    [14]
    魏立业,夏岳,张晓婵,等.重组人脑利钠肽对行直接介入治疗的急性心肌梗死患者心肾保护作用[J].中华老年心脑血管病杂志,2017,19(2):156-159. doi: 10.3969/j.issn.1009-0126.2017.02.012
    [15]
    吴琼,陈还珍,盖婉丽.重组人脑利钠肽治疗急性心肌梗死合并心力衰竭的效果[J].中国心血管杂志,2019,24(3):250-253. https://www.cnki.com.cn/Article/CJFDTOTAL-XIXG201903016.htm
    [16]
    付文科,孙玉发,郝卫军,等.左西孟旦治疗老年缺血性心肌病所致急性失代偿性心力衰竭的疗效和安全性分析[J].中华老年心脑血管病杂志,2017,19(2):153-155. doi: 10.3969/j.issn.1009-0126.2017.02.011
    [17]
    傅涛,荆忱,徐佳,等.冻干重组人脑利钠肽治疗缺血性心肌病室性心律失常和急性心力衰竭的疗效和安全性评价[J].北京医学,2017,39(6):607-610,614. https://www.cnki.com.cn/Article/CJFDTOTAL-BJYX201706024.htm
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Tables(3)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (220) PDF downloads(10) Cited by()
    Proportional views
    Related

    Address：No. 287, Changhuai Road, Bengbu, Anhui Province, 233004, P.R.ChinaphoneNo：0552-3066635； 0552-3051890Email：zhqkyx@163.com

    Copyright © Chinese Journal of General Practice皖ICP备2020018345号-2

    Supported by: Beijing Renhe Information Technology Co., Ltd.    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return